The advice in a representation at BVR Subrahmanyam, secretary of the Ministry of Commerce, recently said: “This will allow manufacturers to export excess production to other countries so that countries and patients in need of these injections can benefit from the benefits. same supplies in a timely manner. In a scenario where there is a peak number of patients / cases in India, said restriction on the export of these products may be reintroduced. “
Removing restrictions on remdesivir and amphotericin-B exports not only benefits patients around the world, but would also allow the industry to meet the global export target of US $ 400 billion set by the United Nations. Prime Minister and a target of US $ 29 billion. set for the pharmaceutical sector, he said.
The council also sent representation to Amit Yadav, Director General, General Directorate of Foreign Trade (DGFT), S Aparna, Secretary, Department of Pharmaceuticals (DoP), Rajesh Bhushan, Secretary, Ministry of Health and Welfare family in this regard.
To ensure the availability of these drugs to needy patients during the second wave of COVID in the country, the DGFT had put in place export restrictions on injections of remdesivir and amphotericin B via notifications dated June 14, respectively. 2021 and June 1, 2021.
The second wave of COVID has resulted in a huge demand for injections of remdesivir as well as injections of the “amphotericin B” antifungal drugs needed for the treatment of mucormycosis.
To meet domestic demand, a number of manufacturers and importers with permission from DCG (I) have increased production and strengthened India’s production capacity for injections of remdesivir and amphotericin-B. At present, India is well stocked to meet any emergency demand for the said drugs.
Earlier, on August 23, 2021, Pharmexcil submitted a detailed representation with a request for relaxation for exports of remdesivir injections.